• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Penn State researchers deliver melanoma drug combo using nanoparticles

March 16, 2017 By Sarah Faulkner

Penn State researchers deliver melanoma drug combo using nanoparticlesResearchers from the Penn State College of Medicine developed a method to deliver a combination of drugs using nanoparticles in the hopes of preventing melanoma cancer cells from developing treatment-resistance. Their work was published in Molecular Cancer Therapeutics and Cancer Letters. 

The team’s CelePlum-777 localized around cancer tumors and delivered a specific ratio of an anti-inflammatory, Celecoxib, and a toxin, Plumbagin, the researchers reported.

“Loading multiple drugs into nanoparticles is one innovative approach to deliver multiple cancer drugs to a particular site where they need to act, and have them released at that optimal cancer cell-killing ratio,”  lead author Raghavendra Gowda said in prepared remarks. “Another advantage is that by combining the drugs, lower concentrations of each that are more effective and less toxic can be used.”

Neither drug can be taken orally and both compounds are toxic to the human body. However, the researchers said its CelePlum-777 can be injected intravenously without the fear of toxicity.

“This drug is the 1st of a new class, loaded with multiple agents to more effectively kill melanoma cells, that has potential to reduce the possibility of resistance development,” senior author Gavin Robertson said. “There is no drug like it in the clinic today and it is likely that the next breakthrough in melanoma treatment will come from a drug like this one.”

The team evaluated its nanoparticle drug-combo in cancer cells grown in dishes and in mice with tumors. CelePlum-777 prevented tumor development in mice with no detectable side effects, according to the researchers, and it stopped proteins from triggering uncontrolled cancer cell proliferation.

Penn State patented the discovery and licensed it to Cipher Pharmaceuticals, which plans to perform the next series of tests required by the FDA.

Filed Under: Featured, Nanoparticles, Oncology, Research & Development Tagged With: Penn State College of Medicine

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS